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Abstract: Porcine endogenous retroviruses (PERVs) are integrated in the genome of all pigs; they 
are released as infectious particles, and under certain conditions they can infect human cells. 
Therefore, they represent a risk when pigs are used as sources of cells, tissues, or organs for 
xenotransplantation. Xenotransplantation is under development due to the increasing shortage of 
human transplants. Whereas most porcine microorganisms which may be able to induce a disease 
(zoonosis) in the transplant recipient can be eliminated, this is not possible in the case of PERVs. 
Antiretroviral drugs which had been developed for the treatment of human immunodeficiency 
virus-1 (HIV-1) infections have been tested in vitro for their efficacy in inhibiting PERV replication. 
Inhibitors of the viral reverse transcriptase and of the integrase have been found effective. The most 
effective inhibitor of the reverse transcriptase was azidothymidine (AZT); the integrase inhibitors 
were the most potent inhibitors of PERV. Although in the past PERV transmission has not been 
observed after experimental or clinical xenotransplantation of pig cells or organs, and although 
PERVs may one day be inactivated in pigs by genome editing using CRISPR/Cas, knowing which 
antiretroviral drugs can effectively restrict PERV infection will still be important. 




Xenotransplantation using pig cells, tissues, or organs is under development due to the 
permanent shortage of human organs for transplantation, and a broader clinical application of 
xenotransplantation products is expected in the near future [1–3]. Xenotransplantation may be 
associated with the transmission of porcine microorganisms able to induce zoonoses in the 
transplanted recipient [4,5]. Whereas most porcine bacteria, fungi, protozoa, and viruses may be 
eliminated by the selection and isolation of uninfected animals, treatment with antiviral drugs, 
vaccination, Cesarean delivery, early weaning, colostrum deprivation, and embryo transfer, this is 
impossible in the case of porcine endogenous retroviruses (PERVs). In contrast to exogenous 
retroviruses such as the human immunodeficiency virus (HIV), which infect only specific target cells 
and integrate their viral genome as an DNA copy called provirus into the genome of only these target 
cells, endogenous retroviruses are the result of a retroviral infection of oocytes and sperm cells, and 
therefore they are integrated in the genome of all cells of an organism [6]. There are three main types 
of PERVs integrated in the genome of pig cells: PERV-A and PERV-B are present in all pigs, and 
PERV-C is present in many pigs, but not all (for review see [7]). Whereas PERV-A and PERV-C can 
infect immortalized and in rare cases also primary human cells, PERV-C is an ecotropic virus 
infecting only pig cells [8–11]. Until now, no transmission of PERV has been observed in experimental 
xenotransplantation and PERV inoculations into small and non-human primates with and without 
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immunosuppression (for review see [7]). PERV transmission was also not observed in the first clinical 
trials of porcine neonatal islet cell clusters for the treatment of diabetes performed in New Zealand 
and Argentina [12,13]. Despite this, different strategies to prevent PERV transmission during 
xenotransplantation or treat PERV infection have been initiated in the past. These strategies include 
PERV-specific vaccines [14–17], antiretroviral drugs [18–25], transgenic pigs expressing a PERV-
specific small-interfering (si)RNA [26–29], and genome editing using zinc finger nucleases (ZFNs) 
[30] or CRISPR/Cas (clustered regularly interspaced short palindromic repeats, CRISPR-associated) 
[31]. Here a review on antiretroviral drugs acting efficiently against PERV will be given. These 
antiretroviral drugs were initially developed to inhibit other retroviruses (mainly HIV-1), and many 
have been licensed for the treatment of HIV infection. Although it may be possible to inactivate all 
proviruses by genome editing and to generate pigs not releasing infectious PERVs, it will still be 
useful to know which antiretroviral drugs are effective against PERV. 
2. Life Cycle of PERV and Targets of Antiretroviral Drugs 
Retroviruses infect their target cells using one or two receptor(s), they transcribe their RNA 
genome into a DNA copy using the viral enzyme reverse transcriptase (RT), and integrate the DNA 
copy into the cellular genome using the viral enzyme integrase (Figure 1). Transcription of the 
proviral genes results in a full-length mRNA encoding for the Gag core proteins and the viral 
enzymes as well as a spliced mRNA encoding for the envelope (Env) proteins. Some retroviruses 
(e.g., HIV-1) have additional spliced mRNA encoding for accessory proteins. The translated proteins 
move to the cell surface, where the virus assembly takes place. After budding of the virus, the viral 
enzyme protease cleaves the Gag proteins, leading to the formation of the core and maturation of the 
virus. The life cycle of retroviruses including that of PERV can be interrupted at different steps acting 
on different viral targets in order to prevent virus replication [7] (Figure 1). First, viral entry can be 
blocked by substances of the drug class entry inhibitors. A subclass of these inhibitors interacts with 
the host co-receptor molecule (co-receptor antagonists) and prevents the binding of viral envelope 
protein. In the other subclass, the fusion inhibitors interact with viral structures to prevent the viral 
entry. Synthetic peptides binding to two helical domains in the transmembrane envelope protein 
hamper fusion with the cell membrane. Second, the RT which transcribes the retroviral RNA genome 
into a DNA copy is the target for two drug classes: (a) the nucleoside or nucleotide reverse 
transcriptase inhibitors (NRTI/NtRTI) and (b) the non-nucleoside reverse transcriptase inhibitors 
(NNRTIs) (for review see [32]) (Table 1). NRTIs are analogs of physiological deoxyribonucleosides 
competing as alternative substrate. The lack of a 3′-OH group on the deoxyribose sugar induces a 
chain-termination of DNA synthesis since phosphodiester bridges can no longer be built. NRTIs are 
pro-drugs, and must be metabolically converted by host-cell kinases to their corresponding active 
triphosphate derivates (NRTI-TPs). NtRTIs are similar to NRTIs, but are monophosphorylated, and 
therefore referred to as a nucleotide analog. The thymidine analogs azidothymidine (AZT, 
zidovudine) and stavudin (d4T), the cytidine analogs lamivudine (3TC) and emtricitabine (FTC), the 
adenosine analog didanosine (DDL) and the guanosine analog abacavir (ABC) were successfully used 
NRTIs to treat HIV-infections. NtRTI are tenofovir (TDF) and adefovir (TAF). 
Table 1. Inhibitory activity of clinically used human immunodeficiency virus-1 (HIV-1) inhibitors on 
porcine endogenous retrovirus (PERV). 




Nucleoside reverse transcriptase 
inhibitors (NRTIs) 
AZT (azidothymidine, also called ZDV, zidovudin) yes [18–22,25] 
3TC (lamivudine) no [18,20] 
d4T (stavudin) no/yes [18,20,22] 
Nucleotide reverse transcriptase 
inhibitors (NtRTIs) 
TAV (adefovir) yes [22,25] 
TDF (tenofovir) yes [22,25] 
Non-nucleoside reverse transcriptase 
inhibitors (NNRTIs) 
EFV (efavirenz) n.t. [20,25] 
ETV (etravirin) n.t. [20,25] 
NVP (nevirapin) no [20,25] 
Integrase inhibitors RAL (raltegravir) yes [24,25] 
Viruses 2017, 9, 213 3 of 8 
 
DTG (dolutegravir) yes [24,25] 
Protease inhibitors 
IDV (indinavir) no [18,20] 
NLV (nelfinavir) no [20] 
SQV (saquinavir) no [20] 
RTV (ritonavir) no [20] 
APV (amprenavir) no [20] 
n.t., not tested. 
The third class, NNRTIs—also RT inhibitors—is chemically distinct from NRTIs, and unlike the 
NRTIs does not require intracellular metabolism for activity. Unlike NRTIs that do not directly inhibit RT, 
NNRTIs bind to a hydrophobic pocket in a subdomain of the enzyme and allosterically slow down DNA 
polymerization significantly. However, recent work has suggested that their inhibition of reverse 
transcription might also be due to effects on RT RNase H activity and/or triphosphate binding. First-
generation NNRTIs were nevirapin (NVP) and efavirenz (EFV) introduced between 1996 and 1998, while 
etravirin (ETV, 2008), and rilpivirin (RPV, 2011) were developed later, therefore called second-generation 
NNRTI. 
 
Figure 1. Life cycle of PERV and targets of four groups of antiretroviral drugs. It is indicated whether 
these inhibitors are available for treatment of PERV infection in vitro. The electron microscopic 
pictures show infection of human 293 cells by PERV and release of virus particles. 
Substances interfering with the integrase belong to the fourth drug class. Integrase enables the 
integration of the proviral DNA copy into the host chromosomal DNA genome in at least four steps. 
First, binding of the integrase to viral DNA (pre-integration complex); second, 3′ processing of the 
dinucleotides at each end of the viral DNA; third, strand transfer from the cytoplasm through a 
nuclear pore into the cell’s nucleus and irreversible binding of viral and host chromosomal DNA; and 
fourth, gap repair. To date, all licensed integrase inhibitors raltegravir (RAL), dolutegravir (DTG) 
and elvitegravir (EVG) act as integrase strand transfer inhibitors (INSTIs). 
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Substances interfering with protease belong to a fifth drug class. Protease acts at a late stage of 
the life cycle, after budding of the newly produced virus from the cellular membrane, it cleaves the 
precursor Gag–Pol(polymerase)-polyprotein into subunits, allowing the maturation of the virus 
particles. If the protease is inhibited and proteolytic splicing is prevented, non-infectious virus 
particles will result (for review see [33]). 
All groups of the here-described retroviral inhibitors have been successfully developed for the 
treatment of HIV-1-infections [34] and have been approved by the Food and Drug Administration (FDA) 
of the USA, the European Medicines Agency (EMEA), and respective agencies in Canada, Japan, and other 
countries. Applying only one substance usually results in the selection of resistance mutations in the viral 
genome. However, a combinatorial application of three substances out of two drug classes (combination 
antiretroviral therapy, cART, previously called highly active antiretroviral therapy, HAART) has been 
very effective in the treatment of HIV-1 with a life-long suppression of virus replication [33–35]. 
3. Inhibitors of Reverse Transcriptase 
The first drug described to be effective against PERV was AZT [18,19]. 3TC and d4T—two other 
nucleoside analogues—did not effectively inhibit PERV [18] (Table 1). Already in 1974, AZT was 
reported by Ostertag et al. [36] to specifically target the Friend virus strain of murine leukemia virus—
a virus closely related to PERV. AZT was also the first drug shown to be effective against HIV-1 [37], 
and it was approved by the FDA for the treatment of HIV infection in 1987 [38]. 
AZT is a thymidine analog, and it selectively inhibits the reverse transcriptase of all retroviruses. 
As described above, cellular enzymes convert AZT to its triphosphate, an active metabolite that 
inhibits DNA synthesis by the RT by chain termination. It also acts on cellular DNA polymerases, but 
inhibits HIV-reverse transcriptase much better than cellular DNA polymerases (for review see [39]). 
The activity of AZT against PERV was later confirmed in three additional studies [20,22,25]. In 
the first of these studies, 11 antiretroviral drugs licensed for HIV-1 therapy were assessed for their 
activities against PERV [20]. AZT was the most effective drug; in all cases, the susceptibility of the 
PERV RT was lower when compared with the susceptibility of the HIV-1 RT. In the second study, 
AZT was also found to be the most active drug [22]. The order of potency was AZT, tenofovir, 
adefovir, and stavudine. In the third study, the NRTI AZT, and the NtRTI adefovir and tenofovir 
were shown to be effective against PERV [25] (Table 1). 
The observed susceptibility of PERV to AZT is not surprising; as mentioned above, AZT has a broad 
range of activity against several retroviruses, and sequence analysis showed that the RT of the murine 
leukemia viruses and of the feline leukemia viruses—also susceptible to the treatment with AZT—share 
more than 70% homology to the RT of PERV [20]. HIV-1 and PERV share only 22.5% amino acid residues 
in the RT, however the sequence homology in the target domain of AZT is much higher. 
Testing the susceptibility of a recombinant PERV RT produced in bacteria, to three NRTI including 
AZT and six NNRTI showed a susceptibility of PERV to AZT and two other NRTI, but almost no 
susceptibility to the NNRTI [21]. To note, PERV recombinant RT had a reduced susceptibility to all three 
NRTI compared with the RT of HIV-1, confirming the results obtained in cell cultures. 
In the case of HIV-1, a resistance usually develops after treatment due to specific mutations in 
the reverse transcriptase [40,41]. In the case of PERV, no studies on resistances to antiretroviral drugs 
have been performed. 
4. Inhibitors of Other PERV Enzymes 
Inhibitors of the integrase were shown to be very effective in inhibiting PERV replication [24,25]. 
The viral enzyme integrase has a key role in the stable integration of the viral DNA copy into the 
cellular genome. Raltegravir and dolutegravir were shown to inhibit PERV effectively [24,25] (Table 
1). When the catalytic domains of the integrase of PERV and HIV-1 were compared, complete 
conservation was observed [25], most likely accounting for the similar patterns of susceptibility to 
raltegravir and dolutegravir. In comparison with AZT, the integrase inhibitors raltegravir and 
dolutegravir were the most potent inhibitors of PERV. 
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Inhibitors developed for the protease of HIV-1 such as indinavir, nelfinavir, saquinavir, 
ritonavir, and amprenavir did not inhibit PERV [20] (Table 1), which may be explained by structural 
differences and the low sequence homology. 
5. Monotherapy versus Combination Treatment 
In using monotherapies for the treatment of HIV-1 infection, it quickly became clear that 
mutations were selected which are associated with resistance. This forced the development of cART. 
According to the World Health Organization (WHO) guidelines, the first-line antiretroviral therapy 
to treat HIV-1 infection for adults should consist of two NRTIs plus a NNRTI or an integrase inhibitor; 
e.g., tenofovir + 3TC (lamivudine or emtricitabine) + efavirenz [42]. After failure on a tenofovir + 3TC 
(lamivudine or emtricitabine)-based first-line regimen, AZT + 3TC as the NRTI backbone should be 
used in second-line regimens; after failure on an AZT or d4T (stavudin) + 3TC (lamivudine)-based 
first-line regimen, a second-line regimen of tenofovir + 3TC as the NRTI backbone should be used. 
Meanwhile, fixed dose combinations (i.e., multiple antiretroviral drugs combined into a single pill) 
were developed—e.g., truvada (tenofovir disoproxil fumarate + emtricitabine) and descovy 
(emtricitabine + tenofovir alafenamide). 
At present, NRTI, NNRTI, and integrase inhibitors have been shown to inhibit PERV in culture 
(Figure 1, Table 1). It remains unclear whether these in vitro assays have translational value to the in 
vivo situation. In addition, no studies on resistance development in vitro have been performed. 
However, based on the use of these drugs for the treatment of HIV-1, dose levels, the bioavailability, 
the absorption, distribution, metabolism, and excretion (ADME), and the adverse side effects of these 
drugs are well known. It also remains unclear whether combinations of drugs that have been 
successful in the treatment of HIV-1 infections will be effective against PERV infections. It is clear 
from the facts summarized in the Introduction section that antiretroviral drugs are only needed in 
cases where patient monitoring indicates PERV transmission. Expecting new achievements in 
genetically modifying pigs (PERV-specific siRNA and CRISPR/Cas-based genome editing), the 
further development of effective drugs and combinations of drugs for PERV actually seems to be 
unnecessary. In the unlikely case that strategies based on siRNA and genome editing are not 
successful, meetings between virologists and transplant physicians should be held to discuss 
recommendations and agree on a consensus for potential treatment protocols. To speculate on the 
use of antiretroviral drugs as a pre-exposure prophylaxis (PrEP)—similar to that now often used to 
prevent HIV infection—would at this time be without a scientific basis. 
6. Inhibitors of PERV Expression 
Whereas the NRTI, NtRTI, NNRTI, and integrase inhibitors can be used as a pre-exposure 
treatment of potential transplant recipients (or in the worst case, to treat PERV infection), another 
strategy intends to reduce the expression of PERV in the donor pigs using drugs. Lower expression 
of mRNA implies lower production of viral proteins and infectious particles and a lower probability 
of infection. This strategy is comparable to the generation of pigs expressing PERV-specific siRNA in 
order to reduce PERV expression [26–29]. In one study, four inhibitors of HIV-1 gene expression were 
analyzed for their activity to inhibit PERV expression [23]. The fluoroquinolone derivative K-37 [43] 
and the bacterial product EM2487, produced from a Streptomyces species [44], were found to be potent 
and selective inhibitors of PERV expression (reducing the expression of viral mRNA) [23]. K-37 and 
EM2487 are also effective inhibitors of HIV-1 [39,40] and human T cell leukemia virus-1 (HTLV-1) 
[45,46] expression. The mechanism of action of both compounds is still unclear; it is assumed that K-
37 interacts with a cellular factor. 
7. Conclusions 
Antiretroviral drugs such as inhibitors of the viral RT (mainly AZT) and integrase inhibitors have 
been shown to effectively inhibit PERV infections in vitro. Integrase inhibitors were the most potent drugs. 
Although there are still no investigations on resistance development after treatment, these drugs are 
Viruses 2017, 9, 213 6 of 8 
 
available for combination antiretroviral therapies shown to be very successful in the case of HIV-1 
treatment. The answer to the question of whether effective drugs (or combinations of drugs) to combat 
PERV infection should be developed, and whether this is actually needed, depends on the success of 
attempts to decrease PERV expression by RNA interference [26–29] or to inactivate all PERV proviruses 
in the pig genome by genome editing (e.g., CRISPR/Cas) [31]. If it becomes possible to generate pigs that 
cannot release infectious PERV, then of course no antiretroviral drugs will be required. However, it would 
still be useful to know whether such drugs are potent and available. 
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